World immunotherapy conference Oct.30, page-17

https://www.fiercebiotech.com/biotech/sitc-merck-highlights-new-lag-3-and-tigit-data

Also on display at SITC this week is a LAG-3 fusion protein from Immutep (formerly Prima Biomed) called eftilagimod alpha, which is a little further ahead in development as it has started a phase 2 trial in non-small cell lung cancer.

Phase 1 data with the drug plus Keytruda in melanoma are being presented at the conference and show an objective response rate of 33% including one complete response in a patient who had progressed on Keytruda alone. Both Merck and Immutep are playing catch-up with Bristol-Myers Squibb in the LAG-3 category, however, as BMS’ relatlimab is now moving into late-stage development after posting encouraging data at ESMO and ASCO this year.​